Abstract
Dapsone, initially synthesized for textile dyeing, gained recognition in the 1930s for its antibacterial properties, leading to its utilization in dermatology for leprosy and dermatitis herpetiformis. Despite US Food and Drug Administration (FDA) approval for these conditions, dapsone’s off-label uses have expanded, making it a valuable option in various dermatologic conditions. This review seeks to highlight the common uses of dapsone in its FDA indications and off-label indications. Diseases in which dapsone is considered first-line therapy or adjunctive therapy are reviewed, with highlights from the resources included. An overview of dapsone’s pharmacokinetics, pharmacodynamics, indications, dosages, and safety profile are also reviewed. Dapsone’s versatility and safety profile make it a cost-effective treatment option in dermatology, particularly for patients with limited access to specialized medications. Ongoing clinical trials are also described exploring dapsone’s efficacy in novel dermatologic uses. Dapsone has been a valuable adjunctive therapy across various dermatologic conditions for years and evidence for its use continues to expand.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Dapsone’s multifaceted antimicrobial and antiinflammatory properties make it an effective treatment for various dermatologic conditions, including leprosy and dermatitis herpetiformis, as well as off-label uses for autoimmune and bullous diseases. |
Despite potential adverse effects, such as gastrointestinal issues and hematologic reactions, dapsone remains a relatively safe and affordable option for long-term treatment of chronic skin diseases with elevated neutrophils and/or eosinophils. |
Special considerations are necessary for its use in pregnant or breastfeeding individuals and children, and regular laboratory monitoring is recommended to manage side effects and ensure patient safety. |
1 Introduction
The use of dapsone, initially synthesized in 1908 by Wittman and Fromm with the aim of developing a sulfonamide-based textile dye, took a turn in the 1930s when its antibacterial effects were discovered during chemotherapeutic experiments [1,2,3,4]. Despite initial concerns over the safety of sulfones, exacerbated by high dosing in animal models, research persisted throughout the twentieth century [2]. Alongside its antibacterial properties, dapsone has antiinflammatory activity, though the underlying mechanism for that activity remained unclear [1]. This dual action paved the way for dapsone’s utilization in various disease processes, with its efficacy established for leprosy and dermatitis herpetiformis in the mid-twentieth century [2, 5, 6].
While dapsone holds US Food and Drug Administration (FDA) indications solely for leprosy and dermatitis herpetiformis, numerous case reports support use for a spectrum of other conditions, including autoimmune and bullous diseases, as well as noninfectious inflammation [2]. Offering a relatively safe, affordable, and effective option, dapsone may be valuable for patients unable to access or afford more specialized medications [7]. This review aims to describe dapsone and its diverse applications in dermatology practice.
2 Methods of Literature Review
A PubMed search was conducted using the terms “dapsone” and “use” and “dermatology” and the filters “review” “systematic review” “humans” and “English” were applied, which yielded 74 results. These articles were reviewed, and a representative list of diseases treated with dapsone as a monotherapy or adjunctive therapy was recorded. References from the initial search were reviewed as additional sources, and a secondary search for the “disease of interest” and “dapsone” was conducted for each dermatologic condition. Data extraction involved recording details such as dosing regimens, treatment outcomes, and other notable findings from each selected study.
3 Overview of Dapsone
3.1 Pharmacokinetics and Pharmacodynamics
Dapsone has a bioavailability exceeding 86% with oral administration, achieving peak plasma concentrations within 2–8 h (Wolf). A standard dose of 100 mg per day results in steady-state plasma concentrations ranging from 2 to 6 µmol [2]. Dapsone undergoes hepatic acetylation by N-acetyltransferase to yield monoacetyl-dapsone (MADDS), which is subsequently hydroxylated by cytochrome P-450 enzymes to generate dapsone hydroxylamine (DDS-NOH) [1]. DDS-NOH is crucial for both the therapeutic efficacy of dapsone and the onset of adverse effects such as methemoglobinemia and hemolysis [1]. Neutrophils also metabolize dapsone, activating the pathway to convert dapsone to DDS-NOH within skin lesions characteristic of inflammatory dermatoses [1]. Human keratinocytes, under the influence of cytokines such as TNF-alpha, IL-1beta, and interferon-gamma, also produce DDS-NOH, contributing to the complexity of dapsone metabolism in various physiological contexts [7].
Dapsone has multifaceted antimicrobial and antiinflammatory properties. Functioning as an antimicrobial agent, dapsone exhibits bacteriostatic activity by impeding the synthesis of dihydrofolic acid, thereby hampering microbial proliferation [1]. Its antiinflammatory effects stem from its ability to modulate neutrophil activity, restraining their inflammatory response [1]. Dapsone’s antiinflammatory action may be due to a dose-dependent inhibition of neutrophil reactivity to immunoglobulin A (IgA) and IgG in patients with bullous pemphigoid [8]. Efficacy for neutrophilic dermatoses, such as Sweet syndrome and pyoderma gangrenosum, may be explained by dapsone’s inhibition of neutrophil respiratory burst occurring in the myeloperoxidase-peroxide halide-mediated cytotoxic system [9]. Additionally, dapsone can exert a dose-dependent suppression of mRNA synthesis in vitro, leading to the inhibition of tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine implicated in various autoimmune disorders [10].
3.2 Indications and Dosage
Dapsone has off-label uses for a wide array of conditions owing to its safety profile suitable for long-term treatment [1]. Chronic skin diseases with elevated levels of neutrophils and/or eosinophils can benefit from dapsone therapy due to its action on these cells [1]. While the US Food and Drug Administration (FDA) has approved dapsone for the treatment of leprosy and dermatitis herpetiformis, its off-label use is extensive, encompassing both monotherapy and adjunctive therapy approaches [9], (Tables 1, 2). Use of dapsone for recluse spider bites (loxoscelism) in the USA is no longer recommended [11, 12]. Support for off-label applications varies, drawing from a spectrum of evidence including randomized controlled trials, case reports, and retrospective chart reviews (Tables 1, 2).
In adults, initial dosages typically range from 50 mg to 100 mg per day, but if treatment objectives are not met within 4–6 weeks, dose escalation to 150–300 mg per day may be considered. Upon achieving therapeutic goals, dosage adjustments should be made to maintain the minimum effective dose [1].
3.3 Safety and Adverse Reactions
While dapsone is widely used with a relatively favorable safety profile, the adverse events associated with dapsone warrant consideration. The most common adverse reactions, which are reported by approximately 55% of patients, are symptoms of gastrointestinal upset such as abdominal pain, anorexia, and vomiting [1, 13]. Other, less common adverse events include pulmonary eosinophilia, hepatitis, nephrotic syndrome, renal papillary necrosis, peripheral neuropathy, and muscle weakness [9, 14].
In addition to these adverse effects, dapsone is often associated with hematologic effects. After dapsone undergoes hepatic N-hydroxylation to DDS-NOH, transport of DDS-NOH into the red blood cells can cause methemoglobinemia, hemolysis, and agranulocytosis [1, 15]. Vitamins C and E may be offered concurrently to reduce the hematologic adverse effects [15]. If methemoglobinemia develops, a “saturation gap” between arterial blood gas and pulse oximetry readings is often used without serum methemoglobin levels [16]. Treatment includes cessation of dapsone and supportive care unless signs of hypoxia or methemoglobin levels exceed 30%, which warrants administration of methylene blue at 1–2 mg/kg (Burke). Activated charcoal may be used to improve methemoglobin clearance in accidental or intentional dapsone overdose [17]. In patients with glucose-6-phosphate dehydrogenase deficiency (G6PD), there is a twofold increase in hemolysis of RBCs, warranting pre-treatment evaluation of G6PD levels of patients prior to dapsone administration [1].
Dapsone use is also associated with exfoliative dermatitis, erythema multiforme, urticaria, erythema nodosum, toxic epidermal necrolysis, and drug-induced lupus erythematosus [1, 9]. A rare, potentially fatal adverse event is dapsone hypersensitivity syndrome (DHS), which has an incidence ranging from 0.5 to 3% [9, 18]. DHS is a systemic syndrome characterized by fever, rash, eosinophilia, and hepatic and pulmonary manifestations that can lead to irreversible organ damage or death without management, with a mortality rate ranging from 12 to 23% [18]. Manifestation of DHS can develop weeks to up to 6 months after dapsone initiation [16]. Treatment for DHS includes discontinuing dapsone and starting systemic steroids with other supportive care [18]. Since the half-life of dapsone is up to 35 days, steroids should be tapered over a period longer than a month [18].
3.4 Special Considerations in Pregnancy and Pediatrics
Special considerations for the use of dapsone in specific populations include pregnant or breastfeeding individuals and children [1]. Dapsone can cross the placental barrier and is detectable in breast milk, posing potential risks to the developing fetus or neonate [1]. Case reports include neonatal hemolysis and cyanosis associated with dapsone use during pregnancy, leading to its classification as a category C drug for use in pregnancy [1, 9]. Dapsone is safe for use in children under the age of 10 years, with recommended dosing at 2 mg per kg of body weight [1, 9].
3.5 Monitoring and Management of Side Effects
Regular laboratory monitoring is recommended for dapsone, with varying frequencies based on institutional protocols and practice standards. Prior to initiating dapsone treatment, it is commonly advised to assess G6PD levels to identify individuals at risk for hemolytic anemia [1, 9]. Baseline complete blood count (CBC) with differential is often recommended with repeat labs every 1–2 weeks for the first month. Following this initial period, CBC may be monitored monthly for 6 months then semiannually [19]. However, specific recommendations may vary by institution or provider. Monitoring of hepatic function tests is recommended at baseline and then periodically [1, 9, 19], with adjustments to dapsone therapy warranted in the presence of elevated bilirubin or liver enzyme levels [1].
3.6 Contraindications
The use of dapsone is contraindicated in individuals with an allergy to dapsone, while caution is advised in those with allergies to other sulfonamide medications [1, 9]. Prior hypersensitivity with agranulocytosis, DHS, or severe anemia are also contraindications [1, 9]. Relative contraindications include conditions such as G6PD deficiency, methemoglobin reductase deficiency, severe hepatopathy, cardiac insufficiency, heart failure, pulmonary disease, and renal impairment [9]. Though G6PD deficiency is considered a relative contraindication, many providers select an alternative if baseline G6PD testing is decreased. Concurrent use of medications that induce methemoglobinemia, such as certain anesthetics such as benzocaine or lidocaine, is also a relative contraindication. It is recommended to discontinue dapsone prior to surgical procedures due to the risk of methemoglobinemia with anesthetics [1]. Patients should also receive counseling regarding the risk of methemoglobinemia associated with the use of spray and cream formulations of local anesthetics when taking dapsone [1].
4 Conclusions
4.1 Clinical Utility and Versatility
Dapsone is indicated to treat leprosy and dermatitis herpetiformis [9], but its synergistic antiinflammatory and antibiotic qualities provide clinical versatility beyond these indications [1]. With effectiveness of dapsone in the treatment of rare, “off-label” indications, such as EED, SPD, and cicatricial pemphigoid, often more than 80%, dapsone is reliable alternative for many rare, difficult to manage diseases. Dapsone was initially thought to be effective in the treatment of neutrophilic dermatoses. However, many eosinophilic dermatoses such as EPF, EAE, and eosinophilic fasciitis and cellulitis have also been successfully managed with dapsone, leading to an expansion of its utility in clinical practice.
Dapsone’s favorable, long-term safety profile [5, 9] and status as an older medication makes it an efficacious and cost-effective treatment alternative for patients who are unable to afford or lack access to newer, specialized medications. Adverse effects such as hemolytic anemia and methemoglobinemia occur infrequently, particularly when prescribed at appropriate doses and with proper monitoring [1]. Though dapsone has an FDA indication for only two diseases, it is often used in the treatment of diseases that lack a standard medication regimen to manage symptoms.
4.2 Ongoing Clinical Trials and Future Use
While dapsone is currently only indicated for two conditions, trials looking into its efficacy in other conditions are ongoing. There are currently two clinical trials investigating the use of dapsone in various dermatologic conditions. One study, with an expected completion date in December 2023, is comparing the efficacy of colchicine, dapsone, and azathioprine in the treatment of skin vasculitides, including primary cutaneous vasculitis, cutaneous polyarteritis nodosa, IgA vasculitis, and Henoch–Schönlein purpura (NCT02939573). This trial aims to evaluate the effectiveness of these medications in managing these conditions over a 6-month period.
Another ongoing study (NCT05984381) is investigating the efficacy and safety of dapsone compared to methotrexate as a steroid-sparing adjunctive therapy for the treatment of bullous pemphigoid. This trial seeks to provide insights into the potential role of dapsone in managing bullous pemphigoid while minimizing the need for systemic corticosteroids. These studies hold promise for expanding our understanding of dapsone’s therapeutic potential and optimizing its use in dermatologic practice.
Continued investigation and trials of dapsone in diseases with pathophysiology similar to those named in the review can further promote dapsone’s future use in dermatology. Dapsone is a versatile option, characterized by its safety, effectiveness, and affordability across various conditions. In many of the conditions discussed with topical corticosteroids therapies as a first line, the addition of dapsone as an adjunctive in recalcitrant diseases or use as a steroid-sparing agent may be beneficial. Dapsone’s status as an older medication with increased availability compared with more specialized medications may provide an option to those in developing regions seeking dermatologic care. This review describes its broad applications, encompassing both FDA-approved indications and off-label uses with efficacy in clinical practice.
References
Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–24. https://doi.org/10.1007/s00403-013-1409-7.
Wolf R, Matz H, Orion E, Tuzun B, Tuzun Y. Dapsone. Dermatol Online J. 2002. https://doi.org/10.5070/D330M4B5KR.
Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997;62(6):827–36. https://doi.org/10.1002/jlb.62.6.827.
Fourneau E, Tréfouël J, Nitti F, Bovet D, Tréfouël J, others. Action anti-streptococcique des derives sulfures organiques. CR Acad Sci. 1937;204(7):1763–6.
Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG. The promin treatment of leprosy. A progress report. Int J Lepr Other Mycobact Dis. 1966;34(3):298–310.
Lang PGJ. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol. 1979;1(6):479–92. https://doi.org/10.1016/s0190-9622(79)80088-2.
Khan F, Roychowdhury S, Nemes R, Vyas P, Woster P, Svensson C. Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes. Toxicology. 2006;218(2–3):90–9. https://doi.org/10.1016/j.tox.2005.10.002.
Thuong-Nguyen VU, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by daspone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Investig Dermatol. 1993;100(4):349–55. https://doi.org/10.1111/1523-1747.ep12471811.
Kurien G, Jamil RT, Preuss CV. Dapsone. In: StatPearls. StatPearls Publishing; 2024. Age and gender as predictors of treatment outcomes with once-daily dapsone 7.5% topical gel for acne vulgaris. J Am Acad Dermatol. 2016;4836(15001):A1–A6. https://doi.org/10.1016/j.jaad.2016.02.007.
Abe M, Shimizu A, Yokoyama Y, Takeuchi Y, Ishikawa O. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-α production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exp Dermatol. 2008;33(6):759–63. https://doi.org/10.1111/j.1365-2230.2008.02864.x.
Forks TP. Brown recluse spider bites. J Am Board Fam Med. 2000;13(6):415–23. https://doi.org/10.3122/15572625-13-6-415.
Vetter, RS; Swanson DL. Bites of recluse spiders. In: UpToDate, Danzl DF, editor. Wolters Kluwer. Accessed 3 Mar 2024.
Kannan G, Vasantha J, Rani NV, et al. Drug usage evaluation of dapsone. Indian J Pharm Sci. 2009;71(4):456. https://doi.org/10.4103/0250-474X.57301.
Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther. 2008;21(4):238–44. https://doi.org/10.1111/j.1529-8019.2008.00204.x.
Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507–13. https://doi.org/10.1111/j.1365-2133.1993.tb00476.x.
Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: case of the blue lady. Can Fam Physician. 2013;59(9):958–61.
Bradberry SM, Vale JA. Multiple-dose activated charcoal: a review of relevant clinical studies. J Toxicol Clin Toxicol. 1995;33(5):407–16. https://doi.org/10.3109/15563659509013749.
Vinod KV, Arun K, Dutta TK. Dapsone hypersensitivity syndrome: a rare life threatening complication of dapsone therapy. J Pharmacol Pharmacother. 2013;4(2):158–60. https://doi.org/10.4103/0976-500X.110917.
UpToDate Lexidrug, Dapsone (systemic). Waltham, MA: UpToDate, Inc. Accessed 27 Mar 2024.
Caproni M, Antiga E, Melani L, Fabbri P, Italian group for cutaneous immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009;23(6):633–8. https://doi.org/10.1111/j.1468-3083.2009.03188.x.
Alexander JO. Dapsone in the treatment of dermatitis herpetiformis. Lancet. 1955;268(6876):1201–2. https://doi.org/10.1016/s0140-6736(55)90693-0.
Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Investig. 1978;62(1):214–20. https://doi.org/10.1172/JCI109109.
Anderson R, Gatner EM, van Rensburg CE, et al. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1981;19(4):495–503. https://doi.org/10.1128/AAC.19.4.495.
Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1-10. https://doi.org/10.1016/j.jaad.2006.10.005.
Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553–61.
Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962–9.
Faghihi G, Khosravani P, Nilforoushzadeh MA, et al. Dapsone gel in the treatment of papulopustular rosacea: a double-blind randomized clinical trial. J Drugs Dermatol. 2015;14(6):602–6.
Ghaoui N, Hanna E, Abbas O, Kibbi A, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787–95. https://doi.org/10.1111/ijd.14761.
Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol. 1988;13(2):67–71. https://doi.org/10.1111/j.1365-2230.1988.tb00659.x.
Wollina U, Krönert C, Koch A, Schönlebe J, Vojvodic A, Lotti T. Erythema elevatum diutinum—two case reports, two different clinical presentations, and a short literature review. Open Access Maced J Med Sci. 2019;7(18):3039–42. https://doi.org/10.3889/oamjms.2019.765.
Katz SI, Gallin JI, Hertz KC, Fauci AS, Lawley TJ. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore). 1977;56(5):443–55.1.
Gulanikar A, Sharma S. A case of erythema elevatum diutinum with dapsone hypersensitivity syndrome. Clin Dermatol Rev. 2019;3(1):92. https://doi.org/10.4103/CDR.CDR_1_18.
Böer A, Misago N, Wolter M, Kiryu H, Wang XD, Ackerman AB. Prurigo pigmentosa: a distinctive inflammatory disease of the skin. Am J Dermatopathol. 2003;25(2):117–29. https://doi.org/10.1097/00000372-200304000-00005.
Mufti A, Mirali S, Abduelmula A, et al. Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): a systematic review of the literature. JAAD Int. 2021;3:79–87. https://doi.org/10.1016/j.jdin.2021.03.003.
Ehmann LM, Meller S, Homey B. Successful treatment of granulomatous rosacea with dapsone. Hautarzt. 2013;64(4):226–8. https://doi.org/10.1007/s00105-013-2556-7.
Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol. 2001;15(5):465–7. https://doi.org/10.1046/j.1468-3083.2001.00325.x.
Kahn G, Rywlin AM. Acropustulosis of infancy. Arch Dermatol. 1979;115(7):831–3.
Findlay RF, Odom RB. Infantile acropustulosis. Am J Dis Child. 1983;137(5):455–7. https://doi.org/10.1001/archpedi.1983.02140310037009.
Dromy R, Raz A, Metzker A. Infantile acropustulosis. Pediatr Dermatol. 1991;8(4):284–7. https://doi.org/10.1111/j.1525-1470.1991.tb00934.x.
Yasuda H, Kobayashi H, Hashimoto T, Itoh K, Yamane M, Nakamura J. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol. 2000;143(1):144–8. https://doi.org/10.1046/j.1365-2133.2000.03604.x.
Chatterjee M, Meru S, Vasudevan B, Deb P, Moorchung N. Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone. Indian J Dermatol. 2012;57(6):495–7. https://doi.org/10.4103/0019-5154.103074.
Moreno ACL, Santi CG, Gabbi TVB, Aoki V, Hashimoto T, Maruta CW. IgA pemphigus: case series with emphasis on therapeutic response. J Am Acad Dermatol. 2014;70(1):200–1. https://doi.org/10.1016/j.jaad.2013.09.037.
Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol. 1987;123(6):783–5.
Aslanova M, Yarrarapu SNS, Zito PM. IgA pemphigus. In: StatPearls. StatPearls Publishing; 2024. Accessed 27 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK519063/.
Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IGA dermatosis. In: StatPearls. StatPearls Publishing; 2024. Accessed 27 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK526113/.
Machado TYS, Enokihara MMSES, Iida TM, Porro AM. Adult linear IgA bullous dermatosis: report of three cases. An Bras Dermatol. 2018;93(3):435–7. https://doi.org/10.1590/abd1806-4841.20187304.
Shetty VM, Pai SB, Rao R. Linear IgA bullous dermatosis presenting as chronic prurigo: unveiling of the diagnosis by serrated pattern analysis. Int J Dermatol. 2018. https://doi.org/10.1111/ijd.14253.
Watts PJ, Khachemoune A. Subcorneal pustular dermatosis: a review of 30 years of progress. Am J Clin Dermatol. 2016;17(6):653–71. https://doi.org/10.1007/s40257-016-0202-8.
Bhargava S, Kumar U, Kroumpouzos G. Subcorneal pustular dermatosis: comprehensive review and report of a case presenting during pregnancy. Int J Womens Dermatol. 2020;6(3):131–6. https://doi.org/10.1016/j.ijwd.2020.02.003.
Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol. 1982;6(2):215–23. https://doi.org/10.1016/s0190-9622(82)70014-3.
Fern AI, Jay JL, Young H, MacKie R. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol. 1992;76(6):332–5. https://doi.org/10.1136/bjo.76.6.332.
Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(2):159–63. https://doi.org/10.1016/s1079-2104(99)70110-1.
Hrin ML, Bashyam AM, Feldman SR, Huang WW. Oral dapsone for the treatment of generalized granuloma annulare: a retrospective case series. J Am Acad Dermatol. 2022;86(4):911–4. https://doi.org/10.1016/j.jaad.2021.03.045.
Steiner A, Pehamberger H, Wolff K. Sulfone treatment of granuloma annulare. J Am Acad Dermatol. 1985;13(6):1004–8. https://doi.org/10.1016/s0190-9622(85)70253-8.
Czarnecki DB, Gin D. The response of generalized granuloma annulare to dapsone. Acta Derm Venereol. 1986;66(1):82–4.
Saied N, Schwartz RA, Estes SA. Treatment of generalized granuloma annulare with dapsone. Arch Dermatol. 1980;116(12):1345–6.
Lindhaus C, Elsner P. Granuloma faciale treatment: a systematic review. Acta Derm Venereol. 2018;98(1):14–8. https://doi.org/10.2340/00015555-2784.
Babalola O, Zhang J, Kristjansson A, Whitaker-Worth D, McCusker M. Granuloma faciale treated with topical dapsone: a case report. Dermatol Online J. 2014;20(8):13030/qt9q7520rx.
Alsorori E, Kiss N, Medvecz M, et al. A case of granuloma faciale successfully treated with systemic dapsone. Dermatol Ther. 2020;33(1): e13162. https://doi.org/10.1111/dth.13162.
El Benaye J, Oumakhir S, Ghfir M, Sedrati O. Dapsone efficacy in lupus miliaris disseminatus faciei: two cases. Ann Dermatol Venereol. 2011;138(8–9):597–600. https://doi.org/10.1016/j.annder.2011.02.019.
Çerman AA, Karabay EA, Yalçın Ö, Altunay IK. Lupus miliaris disseminatus faciei: a case report and brief literature review. Sisli Etfal Hastan Tip Bul. 2018;52(2):142–4. https://doi.org/10.14744/SEMB.2017.39306.
Al-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminatus faciei. J Dermatol. 2011;38(9):864–73. https://doi.org/10.1111/j.1346-8138.2011.01244.x.
Kumano K, Tani M, Murata Y. Dapsone in the treatment of miliary lupus of the face. Br J Dermatol. 1983;109(1):57–62. https://doi.org/10.1111/j.1365-2133.1983.tb03992.x.
Schmidt E, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2002;124(1):157–62. https://doi.org/10.1046/j.1365-2249.2001.01503.x.
Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol. 2009;10(6):383–96. https://doi.org/10.2165/11310740-000000000-00000.
Schmidt E, Kraensel R, Goebeler M, et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis. 2005;76(3):205–9.
Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683–4. https://doi.org/10.1016/s0190-9622(96)80085-5.
Jeffes EW 3rd, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol. 1989;14(2):132–6. https://doi.org/10.1111/j.1365-2230.1989.tb00910.x.
Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32. https://doi.org/10.1001/archderm.144.1.25.
Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699–702. https://doi.org/10.1001/archderm.141.6.699.
Haim S, Birnbaum F. Dapsone in the treatment of pemphigus vulgaris. Dermatology. 1978;156(2):120–3. https://doi.org/10.1159/000250907.
Lepe K, Yarrarapu SNS, Zito PM. Pemphigus foliaceus. In: StatPearls. StatPearls Publishing; 2024.
Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976;94(6):681–6. https://doi.org/10.1111/j.1365-2133.1976.tb05168.x.
Connor B. Herpetiform pemphigus foliaceus responsive to dapsone. Br J Dermatol. 1972;86(1):99–101. https://doi.org/10.1111/j.1365-2133.1972.tb01903.x.
Leibowitz MR, Voss SP. Juvenile pemphigus foliaceous: response to dapsone. Arch Dermatol. 1993;129(7):910.
Galambrun C, Cambazard F, Clavel C, Versini P, Stephan JL. Pemphigus foliaceus. Arch Dis Child. 1997;77(3):255–7. https://doi.org/10.1136/adc.77.3.255.
Mehravaran M, Moln ÁR, et al. Juvenile pemphigus foliaceus: juvenile pemphigus foliaceus. Br J Dermatol. 1998;139(3):496–99. https://doi.org/10.1046/j.1365-2133.1998.02417.x.
Cianchini G, Lembo L, Colonna L, Puddu P. Pemphigus foliaceus induced by radiotherapy and responsive to dapsone. J Dermatol Treat. 2006;17(4):244–6. https://doi.org/10.1080/09546630600921197.
Khachemoune A, Guldbakke KK, Ehrsam E. Pemphigus foliaceus: a case report and short review. Cutis. 2006;78(2):105–10.
Demirçay Z, Baykal C, Demirkesen C. Lichen planus pemphigoides: report of two cases. Int J Dermatol. 2001;40(12):757–9. https://doi.org/10.1046/j.1365-4362.2001.01334.x.
Falk DK, Latour DL, King LE. Dapsone in the treatment of erosive lichen planus. J Am Acad Dermatol. 1985;12(3):567–70. https://doi.org/10.1016/s0190-9622(85)70080-1.
Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol. 2004;5(3):189–97. https://doi.org/10.2165/00128071-200405030-00007.
Takematsu H. Eosinophilic pustular folliculitis: report of two cases with a review of the Japanese literature. Arch Dermatol. 1985;121(7):917. https://doi.org/10.1001/archderm.1985.01660070107029.
Steffen C. Eosinophilic pustular folliculitis (Ofuji’s disease) with response to dapsone therapy. Arch Dermatol. 1985;121(7):921–3.
Malanin G, Helander I. Eosinophilie pustular folliculitis (Ofuji’s disease): response to dapsone but not to isotretinoin therapy. J Am Acad Dermatol. 1989;20(6):1121. https://doi.org/10.1016/S0190-9622(89)80190-2.
Anjaneyan G, Manne S, Panicker VV, Eapen M. Ofuji’s disease in an immunocompetent patient successfully treated with dapsone. Indian Dermatol Online J. 2016;7(5):399–401. https://doi.org/10.4103/2229-5178.190497.
Smith LC, Cox NH. Dapsone treatment for eosinophilic fasciitis. Arch Dermatol. 2008;144(7):845–7. https://doi.org/10.1001/archderm.144.7.845.
Bokotas C, Kouris A, Stefanaki C, Sgotzou T, Christofidou E, Kontochristopoulos G. Wells syndrome: response to dapsone therapy. Ann Dermatol. 2014;26(4):541. https://doi.org/10.5021/ad.2014.26.4.541.
Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006. https://doi.org/10.1001/archderm.142.9.1157.
Coelho de Sousa V, Laureano Oliveira A, Cardoso J. Successful treatment of eosinophilic cellulitis with dapsone. Dermatol Online J. 2016;22(7):13030/qt9v67b10b.
Wallis L, Gilson RC, Gilson RT. Dapsone for recalcitrant eosinophilic annular erythema: a case report and literature review. Dermatol Ther (Heidelb). 2018;8(1):157–63. https://doi.org/10.1007/s13555-017-0214-1.
Manriquez J, Berroeta‐Mauriziano D, Andino‐Navarrete R, Vera‐Kellet C. Eosinophilic annular erythema: complete clinical response with dapsone. Int J Dermatol. 2015. https://doi.org/10.1111/ijd.12736.
Liang SE, Hoffmann R, Peterson E, Soter NA. Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria. JAMA Dermatol. 2019;155(1):90. https://doi.org/10.1001/jamadermatol.2018.3715.
Morgan M, Cooke A, Rogers L, Adams-Huet B, Khan DA. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol In Prac. 2014;2(5):601–6. https://doi.org/10.1016/j.jaip.2014.06.004.
Engin B, Özdemir M. Prospective randomized non‐blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. Acad Dermatol Venereol. 2008;22(4):481–6. https://doi.org/10.1111/j.1468-3083.2007.02510.x.
Nutan F, Ortega-Loayza AG. Cutaneous lupus: a brief review of old and new medical therapeutic options. J Investig Dermatol Sympos Proc. 2017;18(2):S64–8. https://doi.org/10.1016/j.jisp.2017.02.001.
Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13(4):300–7. https://doi.org/10.1007/s11926-011-0180-z.
Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016;232(1):91–6. https://doi.org/10.1159/000441054.
Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172(4):214–7. https://doi.org/10.1159/000249338.
Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus. 1999;8(3):240–3. https://doi.org/10.1191/096120399678847713.
Pate DA, Johnson LS, Tarbox MB. Leukocytoclastic vasculitis resolution with topical dapsone. Cutis. 2017;99(6):426–8.
Nürnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol. 1995;75(1):54–6. https://doi.org/10.2340/00015555755456.
Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458–66. https://doi.org/10.1016/j.jaci.2018.09.007.
Kechichian E, Haber R, Mourad N, El Khoury R, Jabbour S, Tomb R. Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol. 2017;56(5):486–95. https://doi.org/10.1111/ijd.13584.
Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea. 2007;26(2):215–9. https://doi.org/10.1097/ICO.0b013e31802eb078.
Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058–60.
Kaur S, Gupta D, Garg B, Sood N. Neutrophilic dermatosis of dorsal hands. Indian Dermatol Online J. 2015;6(1):42–5. https://doi.org/10.4103/2229-5178.148940.
Micallef D, Bonnici M, Pisani D, Boffa MJ. Neutrophilic dermatosis of the dorsal hands: a review of 123 cases. J Am Acad Dermatol. 2023;88(6):1338–44. https://doi.org/10.1016/j.jaad.2019.08.070.
Galaria NA, Junkins-Hopkins JM, Kligman D, James WD. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J Am Acad Dermatol. 2000;43(5):870–4. https://doi.org/10.1067/mjd.2000.109286.
DiCaudo DJ, Connolly SM. Neutrophilic dermatosis (pustular vasculitis) of the dorsal hands: a report of 7 cases and review of the literature. Arch Dermatol. 2002. https://doi.org/10.1001/archderm.138.3.361.
Ramos FS, Ferreira FR, Rabay FMDO, Lira MLDA. Neutrophilic dermatosis of the dorsal hands: response to dapsone monotherapy. An Bras Dermatol. 2018;93(5):730–2. https://doi.org/10.1590/abd1806-4841.20187488.
Gillihan R, Farahbakhsh N, Motaparthi K. Neutrophilic urticarial dermatosis without underlying systemic disease. J Clin Aesthet Dermatol. 2020;13(3):20–1.
Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: a review. Ann Dermatol Vénéréol. 2018;145(12):735–40. https://doi.org/10.1016/j.annder.2018.06.010.
Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine. 2009;88(1):23–31. https://doi.org/10.1097/MD.0b013e3181943f5e.
Cohen PR. Sweet’s syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2(1):34. https://doi.org/10.1186/1750-1172-2-34.
Aram H. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Response to dapsone. Arch Dermatol. 1984;120(2):245–7.
Mahajan VK, Sharma NL, Sharma RC. Sweet’s syndrome from an Indian perspective: a report of four cases and review of the literature. Int J Dermatol. 2006;45(6):702–8. https://doi.org/10.1111/j.1365-4632.2006.02622.x.
Shibata K, Tateishi T, Yamasaki R, Ohyagi Y, Kira J. Successful treatment of a case of steroid-dependent neuro-Sweet disease with dapsone. Rinsho Shinkeigaku. 2010;50(4):257–61. https://doi.org/10.5692/clinicalneurol.50.257.
Keisham C, Sarkar R, Garg V, Chugh S. Ashy dermatosis in an 8-year-old Indian child. Indian Dermatol Online J. 2013;4(1):30. https://doi.org/10.4103/2229-5178.105466.
Bahadir S, Çobanoglu Ü, Çimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. 2004;43(3):220–2. https://doi.org/10.1111/j.1365-4632.2004.01984.x.
Correspondence G-Y. Int J Dermatol. 1998;37(10):796–8. https://doi.org/10.1046/j.1365-4362.1998.00522.x.
Nguyen K, Khachemoune A. Ashy dermatosis: a review. Dermatol Online J. 2019;25(5):13030/qt44f462s8.
Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267–79. https://doi.org/10.1111/j.1346-8138.2002.tb00263.x.
Mangelsdorf HC, White WL, Jorizzo JL. Behçet’s disease. J Am Acad Dermatol. 1996;34(5):745–50. https://doi.org/10.1016/S0190-9622(96)90006-7.
Jacyk WK. Behçet’s disease in South African blacks: report of five cases. J Am Acad Dermatol. 1994;30(5):869–73. https://doi.org/10.1016/S0190-9622(94)70102-4.
Estève C, Samson M, Guilhem A, et al. Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients. Kuwana M, ed. PLoS ONE. 2017;12(10):e0187296. https://doi.org/10.1371/journal.pone.0187296.
Durand JM, Lefèvre P, Hovette P, Mongin M, Soubeyrand J. Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol. 1991;78(3):459–60. https://doi.org/10.1111/j.1365-2141.1991.tb04467.x.
Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults—a report on 90 patients. Eur J Haematol. 2005;75(4):328–31. https://doi.org/10.1111/j.1600-0609.2005.00545.x.
Godeau B, Durand J, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97(2):336–9. https://doi.org/10.1046/j.1365-2141.1997.412687.x.
Paquet P, Piérard GE. Traitement par dapsone de la folliculite décalvante. Ann Dermatol Vénéréol. 2004;131(2):195–7. https://doi.org/10.1016/S0151-9638(04)93570-3.
Broussard KC, Berger TG, Rosenblum M, Murase JE. Erosive pustular dermatosis of the scalp: a review with a focus on dapsone therapy. J Am Acad Dermatol. 2012;66(4):680–6. https://doi.org/10.1016/j.jaad.2011.10.011.
Feramisco J, George T, Schulz S, Ma H, Metze D, Steinhoff M. Disseminated erosive pustular dermatosis also involving the mucosa: successful treatment with oral dapsone. Acta Derm Venerol. 2012;92(1):91–2. https://doi.org/10.2340/00015555-1162.
Di Bartolomeo L, Ceravolo I, Borgia F, Vaccaro F, Guarneri C, Vaccaro M. Treatment of erosive pustular dermatosis of the scalp: our experience and review of unconventional topical drugs. Eur Rev Med Pharmacol Sci. 2023;27(3):1023–6. https://doi.org/10.26355/eurrev_202302_31197.
Karanfilian KM, Wassef C. Erosive pustular dermatosis of the scalp: causes and treatments. Int J Dermatol. 2021;60(1):25–32. https://doi.org/10.1111/ijd.14955.
Junejo MH, Kentley J, Rajpopat M, Tan XL, Mohd Mustapa MF, Harwood CA. Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review*. Br J Dermatol. 2021;184(1):25–33. https://doi.org/10.1111/bjd.19026.
Rabindranathnambi A, Jeevankumar B. Dapsone in hidradenitis suppurativa: a systematic review. Dermatol Ther (Heidelb). 2022;12(2):285–93. https://doi.org/10.1007/s13555-021-00674-x.
Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GBE. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342–6. https://doi.org/10.1159/000329023.
López-Llunell C, Riera-Martí N, Gamissans M, Romaní J. Dapsone in hidradenitis suppurativa: a case series of 56 patients. Dermatol Ther. 2021;34(6): e15161. https://doi.org/10.1111/dth.15161.
Murray G, Hollywood A, Kirby B, Hughes R. Dapsone therapy for hidradenitis suppurativa. Br J Dermatol. 2020;183(4):767–8. https://doi.org/10.1111/bjd.19136.
Baroudi B, Bashyam AM, Feldman SR, Pichardo RO. Dapsone to treat moderate-to-severe hidradenitis suppurativa: a retrospective case-series. J Drugs Dermatol. 2023;22(11):e12–6. https://doi.org/10.36849/JDD.4936.
Funding
Open access funding provided by the Carolinas Consortium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflicts of interest
S.R. Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. K.K. Lovell, R.I. Momin, H. S. Sangha, and R. O. Pichardo have no conflicts of interest to disclose.
Author contributions
Katie K. Lovell: conceptualization, investigation, writing—original draft, writing—review and editing, project administration. Rushan I. Momin: investigation, writing—original draft, writing—review and editing. Harneet Singh Sangha: investigation, writing—original draft, writing—review and editing. Steven R. Feldman: supervision, project administration, writing—review and editing. Rita O. Pichardo: conceptualization, supervision, project administration, writing—review and editing.
Ethics approval
Not applicable.
Informed consent
Not applicable.
Data and code availability
Not applicable.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lovell, K.K., Momin, R.I., Sangha, H.S. et al. Dapsone Use in Dermatology. Am J Clin Dermatol 25, 811–822 (2024). https://doi.org/10.1007/s40257-024-00879-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-024-00879-8